Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 Next >
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Provides Namodenoson Patent Update
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.